-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Colorectal cancer (CRC) ranks fourth in incidence and fifth in mortality among malignant tumors in China.
Colorectal cancer (CRC) ranks fourth in incidence and fifth in mortality among malignant tumors in China.
Include patients who have undergone next-generation sequencing (NGS) from 2017.
Include patients who have undergone next-generation sequencing (NGS) from 2017.
Patient clinical characteristics
Patient clinical characteristicsMutation type
Mutation typeThe median progression-free period (DFS) of patients with HER2 genetic changes was 17.
The median progression-free period (DFS) of patients with HER2 genetic changes was 17.
DFS analysis
DFS analysisTwenty-five patients with MSI-H received PD-1 monoclonal antibody treatment, of which 9 had HER2 mutations and 16 had no HER2 changes.
Twenty-five patients with MSI-H received PD-1 monoclonal antibody treatment, of which 9 had HER2 mutations and 16 had no HER2 changes.
Anti-PD1 treatment for DFS
Anti-PD1 treatment for DFSIn summary, the proportion of MSI-H found in HER2 mutation cases is higher, but MSI-H is not found in HER2 amplified cases.
In summary, the proportion of MSI-H found in HER2 mutation cases is higher, but MSI-H is not found in HER2 amplified cases.
Original source:
ncbi.
ncbi.
nlm.
nih.
gov/?term=Qiu+MZ&cauthor_id=33844372">Miao-Zhen Qiu , ncbi.
nlm.
nih.
gov/?term=He+CY&cauthor_id=33844372">Cai-Yun He , ncbi.
nlm.
nih.
gov/?term=Yang+XH&cauthor_id=33844372">Xin-Hua Yang ,et al.
Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma.
Oncologist.
2021 Apr 12.
doi: 10.
1002/onco.
13786.
Online ahead of print.
ncbi.
nlm.
nih.
gov/?term=Qiu+MZ&cauthor_id=33844372">Miao -Zhen Qiu ncbi.
nlm.
nih.
gov/?term=He+CY&cauthor_id=33844372">Cai-Yun He ncbi.
nlm.
nih.
gov/?term=Yang+XH&cauthor_id=33844372">Xin-Hua Yang leaves a message here